merck

Documents about merck

• BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)#1093677ClinicalTrials.gov
• Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)#862941ClinicalTrials.gov
• W911QY21C0031 — MERCK SHARP & DOHME LLC — Department of Defense ($2,205,000,834)#604607USAspending
• GXR RM China BE Study (Darmstadt - Jiangsu)#321681ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)#1008205ClinicalTrials.gov
• Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates#148715ClinicalTrials.gov
• Merck KGaA v Merck Sharp & Dohme LLC & Ors [2026] EWHC 1113 (Ch) (15 May 2026)#184673BAILII
• DDI Study of Evobrutinib and Carbamazepine#1093433ClinicalTrials.gov
• Effect of Food on Peposertib PK#1164132ClinicalTrials.gov
• Relative Bioavailability of Evobrutinib Tablet Batches#832511ClinicalTrials.gov
• Effect of Renal Impairment on Enpatoran Pharmacokinetics#1182435ClinicalTrials.gov
• HHSD200201458150C — MERCK SHARP & DOHME LLC — Department of Health and Human Services ($1,480,605,084)#604812USAspending
• HHSD200201793273C — MERCK SHARP & DOHME LLC — Department of Health and Human Services ($1,453,663,190)#604824USAspending
• HHSD200201354509C — MERCK SHARP & DOHME LLC — Department of Health and Human Services ($1,372,607,194)#604861USAspending
• HHSD200201250133C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,369,650,661)#604862USAspending
• HHSD200201034037C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,327,365,536)#604899USAspending
• HHSD200200929370C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,319,368,887)#604906USAspending
• HHSD200200720306C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,317,743,050)#604907USAspending
• HHSD200201138200C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,273,848,674)#604937USAspending
• HHSD200200824718C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,180,245,725)#604998USAspending
• HHSD200200615819C — MERCK SHARP & DOHME CORP. — Department of Health and Human Services ($1,035,982,833)#605122USAspending
• Enpatoran Human Mass Balance and Absolute Bioavailability Study#1074158ClinicalTrials.gov
• Sugammadex Hypersensitivity Study (Study P06042)#18715ClinicalTrials.gov
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)#803271ClinicalTrials.gov
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)#853104ClinicalTrials.gov
• Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants#1101911ClinicalTrials.gov
• Martin and Harris Private Ltd v. Merck & Co Inc#470931Villanova University Charles Widger School of Law Digital Repository
• JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study#1007971ClinicalTrials.gov
• Glucophage Immediate Release (GIR) China Bioequivalence Study#127833ClinicalTrials.gov
• Tecemotide (L-BLP25) in Rectal Cancer#174936ClinicalTrials.gov
• Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors#852709ClinicalTrials.gov
• A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy#1138885ClinicalTrials.gov
• MK0767 and Metformin Combination Study (0767-028)#121301ClinicalTrials.gov
• Study A - MK0767 Monotherapy Study#451437ClinicalTrials.gov
• Post Marketing Surveillance Study of Cuprimine#1113339ClinicalTrials.gov
• Remicade Safety Line (Study P03236)(COMPLETED)#1138757ClinicalTrials.gov
• An Extension Study for Patients Previously Treated With ARQ 501#833275ClinicalTrials.gov
• ARQ 197 in Subjects With Metastatic Solid Tumors#967030ClinicalTrials.gov
• The OBSTACLE Hypoglycemia Study (MK-0000-158)#67777ClinicalTrials.gov
• ZOSTAVAX(R) Local Registration Trial (V211-019)#230478ClinicalTrials.gov
• ALPHA Sitagliptin Add on to Metformin (0431-103)#349919ClinicalTrials.gov
• Rotavirus Efficacy and Safety Trial (REST)(V260-006)#674787ClinicalTrials.gov
• MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)#828279ClinicalTrials.gov
• Safety and Tolerability of Odanacatib (0822-059)#918010ClinicalTrials.gov
• Re-examination Study For Varivax (V210-059 AM2)#1010371ClinicalTrials.gov
• GARDASIL Reexamination Study (V501-059)#1096244ClinicalTrials.gov
• MSD Belzutifan PAS#1162162ClinicalTrials.gov
• An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin#1046405ClinicalTrials.gov
• Glucophage XR® Observational Study#175067ClinicalTrials.gov
• Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)#238310ClinicalTrials.gov